15th Jul 2022 12:04
15 July 2022
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the issue and allotment of 321,292 ordinary shares of £0.05 pursuant to vesting of the deferred bonus share awards granted under the Diurnal Group plc Long Term Incentive Plan details of which were announced on 2 August 2021, including 163,792 ordinary shares to persons discharging managerial responsibilities ("PDMR").
PDMR Total number of New Nature of issuance
Ordinary Shares issued
Richard Bungay 84,000 Vesting of deferred bonus award
Richard Ross 26,892 Vesting of deferred bonus award
John Porter 30,500 Vesting of deferred bonus award
Stewart Jones 22,400 Vesting of deferred bonus award
The shares were issued under the Company's Employee Benefit Trust scheme.
Following the issue of shares, the total beneficial interest of Richard Bungay is 337,578 Ordinary Shares, representing 0.20% of the total voting rights, the total beneficial interest of Richard Ross and his connected parties is 2,284,047 Ordinary Shares, representing 1.34% of the total voting rights, the total beneficial interest of John Porter is 143,245 Ordinary Shares, representing 0.08% of the total voting rights, and the total beneficial interest of Stewart Jones is 130,282 Ordinary Shares, representing 0.08% of the total voting rights.
The new ordinary shares are being issued pursuant to the Company's block admission facility, details of which were announced on 13 December 2021. The new ordinary shares will rank pari passu with the existing shares of common stock of the Company. Following the issue of shares, the Company's issued ordinary share capital will consist of 170,040,825 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 170,040,825.
The above figure of 170,040,825 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Richard Bungay | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Interim Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Nil | 84,000 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price |
| ||||
e)
| Date of the transaction
| 15 July 2022 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Richard Ross | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Scientific Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Nil | 26,892 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price |
| ||||
e)
| Date of the transaction
| 15 July 2022 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| John Porter | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Medical Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Nil | 30,500 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price |
| ||||
e)
| Date of the transaction
| 15 July 2022 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Stewart Jones | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Operations Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Nil | 22,400 |
| |||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price |
| ||||
e)
| Date of the transaction
| 15 July 2022 | |||
f)
| Place of the transaction
| XLON | |||
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Richard Bungay, Interim Chief Executive Officer |
|
| |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl |
|
Corporate Broking: Rupert Dearden |
|
| |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 |
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown |
|
Corporate Broking: Nick Adams, Nick Harland |
|
| |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Alex Davis | |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
Related Shares:
DNL.L